Human umbilical cord mesenchymal stem cell not checked

Sclnow Biotechnology Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);”In the company’s words, NCT03383081 on ClinicalTrials.gov
Tested for
Osteoarthritis, Knee, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Lumbar Discogenic Pain
Main trialPhase 2
“The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease”In the company’s words, NCT03383081 on ClinicalTrials.gov
Other names
mesenchymal stem cells · umbilical cord mesenchymal stem cell

Other drugs for Osteoarthritis, Knee

All 34 drugs for Osteoarthritis, Knee

Coming up3

Changes1

Last 90 days

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2026 The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis
Phase 2Not yet recruiting 30 Jun 2027 Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Phase 1Recruiting 31 Dec 2026 The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain
Phase 1Completed 1 Jun 2021 hUC Mesenchymal Stem Cells (19#iSCLife®-CSD) Therapy for Patients With Healing Poor After Uterus Injury
Phase 1Suspended 30 Jun 2027 SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Human umbilical cord mesenchymal stem cell

Following is part of Solo: you see every change to Human umbilical cord mesenchymal stem cell the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in